Kush Parmar

Managing Partner

2010

5AM Ventures is an early-stage venture capital firm focused on building next-generation life science companies. Founded in 2002, 5AM Ventures has over $1.5 billion USD under management. The firm has offices in San Francisco, CA and Boston, MA. Formed by successful industry executives and experienced venture capitalists, the 5AM team takes a focused, hands-on approach to company building. In addition to leading investments and contributing as board members of its portfolio companies, 5AM is directly involved in company strategy, management recruiting, business development and fundraising and often takes on short-term operating roles.

Board Of Directors

2018

Rallybio was established to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders. The founders of the company – Martin Mackay, PhD, Steve Uden, MD, and Jeffrey Fryer, CPA – are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. For more information, please visit www.rallybio.com.

Chairman Of The Board Of Directors

2016

Entrada Therapeutics is a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics. www.entradatx.com

Co-Founder

2019

Mission-driven enterprise to spearhead access to cell and gene therapies for cancer patients in India. Co-founded by Kiran Mazumdar Shaw, Kush Parmar and Siddhartha Mukherjee. Headquartered in Bangalore, India.

Research Council Member

2018

Advisory Council, Department of Molecular Biology

2015

Member, Scientific Advisory Board

2014

Grace Wilsey and other affected patients like her have two damaging mutations in their NGLY1 gene. Led by Grace's parents Matt and Kristen, an international team of clinicians and researchers has come together in an unprecedented way of open collaboration to understand the disease and to develop a cure. It my privilege to be part of their efforts. Please join us and visit the site at www.gracescience.org

Board Of Directors

2013

Audentes (NASDAQ: BOLD) is a biotechnology company committed to the development and commercialization of innovative new treatments for people with life-threatening rare diseases through the application of adeno-associated virus (AAV) gene therapy technology. www.audentestx.com

Board Member

2019

At Ensoma, we believe every person, no matter where they are in the world, should have access to innovative technologies that are changing the way we treat disease. Harnessing the power of our Engenious™ vectors, our therapies can be delivered in a simple, single injection. We are poised to bring life-changing therapies to people all over the world.

Founding CEO, Chairman

2015 - 2023

Homology Medicines (NASDAQ: FIXX) is a genetic medicines company translating proprietary, cutting-edge gene editing and gene therapy technology into cures for patients with rare diseases. www.homologymedicines.com